Search - tctmd.com

Displaying 101 - 120 of 234

Sort: Relevancy | Date

News Daily News

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

Michael O'Riordan

March 29, 2023

News Daily News

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

L.A. McKeown

March 27, 2023

News Daily News

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

L.A. McKeown

March 24, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

News Opinion CV Team Dispatch

March 2023 News Roundup

L.A. McKeown

March 15, 2023

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

L.A. McKeown

March 14, 2023

News Conference News ACC 2023

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

L.A. McKeown

March 06, 2023

News Conference News ACC 2023

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

L.A. McKeown

March 04, 2023

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Opinion CV Team Dispatch

February 2023 News Roundup

L.A. McKeown

February 15, 2023

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

L.A. McKeown

February 02, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Features

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

Shelley Wood

December 20, 2022

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

Todd Neale

December 09, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

L.A. McKeown

November 11, 2022

News Conference News AHA 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

Todd Neale

November 07, 2022

Advertisement

Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

March 2023 News Roundup

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

What’s Going to Be Hot at ACC/WCC 2023?

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

February 2023 News Roundup

Vast Majority of HFrEF Patients Eligible for Vericiguat

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Query Use of Nontraditional Therapies for HF at Every Visit: AHA Statement

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content